Overview

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of PA-824 at 50, 100, 150 and 200 mg per day in adult patients with newly diagnosed, uncomplicated, smear positive tuberculosis (TB). A control group will receive standard TB treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Global Alliance for TB Drug Development